M32.12 Insurance Policy Changes

ICD-10 M32.12 is officially defined as "Pericarditis in systemic lupus erythematosus." code M32.12 is referenced in 7 tracked payer policy changes from Aetna, Blue Cross & Blue Shield of Mississippi, and 1 other payer. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code M32.12 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Aetna · Identified Oct 3, 2026Medium impact
Rilonacept (Arcalyst) (CPB 0770, reviewed 2026-09-11)
Aetna covers rilonacept (Arcalyst) for commercial medical plans for three indications: cryopyrin-associated periodic syndromes (CAPS) in members 12 years of age or older, deficiency of interleukin-1 receptor antagonist (DIRA) in members weighing at least 10 kg, and recurrent pericarditis (RP) in members 12 years of age or older. The medication must be prescribed by or in consultation with a rheumatologist or immunologist for CAPS and DIRA, and by a cardiologist, rheumatologist, or immunologist for RP. All other indications are considered experimental, investigational, or unproven, and concomitant use with any other biologic drug or targeted synthetic drug is considered experimental, investigational, or unproven.
Aetna · Identified Aug 16, 2026Medium impact
Rilonacept (Arcalyst) (CPB 0770, reviewed 2026-03-25)
Aetna's Clinical Policy Bulletin for rilonacept (Arcalyst) addresses the drug for commercial medical plans. Aetna considers it medically necessary for cryopyrin-associated periodic syndromes in members 12 years of age or older, for deficiency of interleukin-1 receptor antagonist (DIRA) in members weighing at least 10 kg, and for recurrent pericarditis in members 12 years of age or older, when each indication's criteria are met. The drug must be prescribed by or in consultation with a rheumatologist or immunologist for CAPS and DIRA, or a cardiologist, rheumatologist, or immunologist for recurrent pericarditis, and Aetna considers all other indications experimental, investigational, or unproven.
Blue Cross & Blue Shield of Mississippi · Identified Jun 20, 2026Medium impact
Systemic Lupus Erythematosus (SLE) & Lupus Nephritis (LN)
Benlysta (belimumab) requires prior authorization for active systemic lupus erythematosus (SLE) and active lupus nephritis (LN). Lupkynis (voclosporin) and Saphnelo (anifrolumab-fnia) are considered not medically necessary because other formulary alternatives are covered by the plan for these conditions. The most recent review, dated 02/24/2026, revised the medically necessary criteria for members with active SLE without active lupus nephritis.
Blue Cross & Blue Shield of Mississippi · Identified Jun 20, 2026Medium impact
State and School Employees' Health Insurance Plan - Systemic Lupus Erythematosus (SLE) & Lupus Nephritis (LN)
Benlysta (belimumab) may be considered medically necessary for members with active systemic lupus erythematosus (SLE) with or without active lupus nephritis (LN) when the listed criteria are met. Saphnelo (anifrolumab-fnia) is considered not medically necessary because other formulary alternatives are covered by the Plan for treatment of active SLE. The most recent review, dated 02/24/2026, revised the medically necessary criteria for individuals with active SLE without active lupus nephritis.
Independence Blue Cross · Identified Jul 23, 2026Low impact
MA08.057d, Belimumab (Benlysta®) for Intravenous Use
Independence Blue Cross reissued Medicare Advantage Policy MA08.057d on 07/22/2026 to communicate its continuing position on belimumab (Benlysta) for intravenous use in systemic lupus erythematosus and lupus nephritis. A guideline restriction on subcutaneous dosing for pediatric patients was removed to align with current FDA labeling. Coverage criteria for SLE and lupus nephritis remain unchanged for patients age 5 and older meeting specified clinical requirements.
Independence Blue Cross · Identified Jun 19, 2026Low impact
MA08.140c, Anifrolumab-fnia (Saphnelo®)
Independence Blue Cross reissued Medicare Advantage policy MA08.140c on 04/29/2026 with no substantive changes to anifrolumab (Saphnelo) coverage. The policy continues to cover this biologic for moderate-to-severe systemic lupus erythematosus (SLE) in adults on standard therapy, with continuation therapy requiring documented disease improvement or stabilization. This is a routine policy restatement with no new billing or clinical requirements.
Independence Blue Cross · Identified Jun 19, 2026Low impact
08.01.82c, Anifrolumab-fnia (Saphnelo®)
Independence Blue Cross reissued Policy 08.01.82c with no substantive changes to anifrolumab-fnia (Saphnelo®) coverage for moderate to severe SLE. The policy maintains existing coverage criteria for initial therapy and continuation therapy, requiring documentation of disease improvement/stabilization using validated scoring instruments (SLEDAI-2K, BILAG, or PGA). No billing workflow changes are required.

Watch M32.12

Get one email when a payer policy names M32.12, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

No account needed. We send a confirmation link first, and every email has a one-click stop link.

FREQUENTLY ASKED QUESTIONS

What insurance policy changes affect code M32.12?

There are 7 tracked policy changes affecting code M32.12, including updates from Aetna, Blue Cross & Blue Shield of Mississippi, Independence Blue Cross. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code M32.12?

Payers that have issued tracked updates for code M32.12 include: Aetna, Blue Cross & Blue Shield of Mississippi, Independence Blue Cross.

How do I get notified when code M32.12 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code M32.12. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code M32.12?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

All billing codes J3590 C9399 J3490 99215 99213 99202

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Rilonacept (Arcalyst) (CPB 0770, reviewed 2026-09-11)

Rilonacept (Arcalyst) (CPB 0770, reviewed 2026-03-25)

Systemic Lupus Erythematosus (SLE) & Lupus Nephritis (LN)

State and School Employees' Health Insurance Plan - Systemic Lupus Erythematosus (SLE) & Lupus Nephritis (LN)

MA08.057d, Belimumab (Benlysta®) for Intravenous Use

MA08.140c, Anifrolumab-fnia (Saphnelo®)

08.01.82c, Anifrolumab-fnia (Saphnelo®)

What insurance policy changes affect code M32.12?

Which payers have updated policy for code M32.12?

How do I get notified when code M32.12 policy changes?

Why do payers change policies for code M32.12?